Accentia enters strategic agreement with Baxter to purchase Cytoxan drug
Links shared publicly online about this topic.
- 692total visits
Accentia enters strategic agreement with Baxter to purchase Cytoxan drug
Accentia Biopharmaceuticals, Inc. today announced a strategic agreement with Baxter Healthcare Corporation to provide Accentia with the exclusive, worldwide right to purchase Baxter's cyclophosphamide, which is marketed under the brand name Cytoxan, for the treatment of designated autoimmune diseases including multiple sclerosis.
View full resource at news-medical.net
Tags: Autoimmune Disease, Drug, Healthcare, Oncology, News, disease
Most Recently Shared on November 29, 2010 at 2:58 pm By:
Oncology News: Accentia enters strategic agreement with Baxter to purchase Cytoxan drug: Accentia Biopharmaceuti... http://bit.ly/h6biIM
Advertisement
